MERYL SCICHILONE: Open Payments
NPI 1013608645 · PORTLAND, ME. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,317 in 137 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $851 · 2025 $3,317
Food & beverage: $3,217Education: $100
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 31 | $1,032 |
| Regeneron Healthcare Solutions, Inc. | 22 | $468 |
| GENZYME CORPORATION | 16 | $429 |
| Novartis Pharmaceuticals Corporation | 16 | $257 |
| GlaxoSmithKline, LLC. | 15 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $166 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $153 |
| CSL Behring | 5 | $139 |
| Amgen Inc. | 4 | $103 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
Products named: DUPIXENT, TEZSPIRE, BREZTRI, AIRSUPRA, NUCALA, FASENRA, NEFFY, Rhapsido.
Industry payments across ME — which companies pay providers there.
